Referência e Estudos Científicos – Composição da Formula – VariFrancy

  1. Rohdewald, P., (2002). “A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology.” Int J Clin Pharmacol Ther. 40. 158-168. doi: 10.5414/CPP40158 . 
  2. Belcaro, S., Dugall, M., Luzzi, R., Hosoi, M., Corsi, M. et al. (2014). “Improvements of venous tone with pycnogenol in chronic venous insufficiency: an ex vivo study in venous segments.” International Journal of Molecular Sciences, 23(1), 047-052. doi: 10.1055/s-0033-1363785.
  3. Breuss, Johannes M., Atanas, G. Atanasov e Uhrin, P. 2019. “Resveratrol and its effects on the vascular system.” International Journal of Molecular Sciences, 20 (7): 1523. doi: 10.3390/ijms20071523.
  4. Shrikanta, A., Kumar, A e Govindaswamy, V. (2015). “Resveratrol content and antioxidant properties of underutilized fruits.” J Food Sci Technol, 52(1), 383–390. doi:  10.1007/s13197-013-0993-z.
  5. Ho Lim, S. e Choi, C. (2019). “Pharmacological properties of Morus nigra L. (black mulberry) as a promising nutraceutical resource.” nutrients, 11(2), 437. doi: 10.3390/nu11020437.
  6. J. Hewlings, S. e S.Kalman, D. (2017). “Curcumin: a review of its effects on human health.” foods, 6(10), 92. doi: 10.3390/foods6100092.
  7. Campbell, M. e Fleenor, B. (2018). “The emerging role of curcumin in improving vascular dysfunction: a review.” Critical Reviews in Food Science and Nutrition, 58(16), 2790-2799. doi: 10.1080/10408398.2017.1341865. 
  8. Stamenkovska, M., Hadzi-Petrushev, N., Nikodinovski, A. et al. (2021) “Application of curcumin and its derivatives in the treatment of cardiovascular diseases: a review.” International Journal of Food Properties, 24(1), 1510-1528. doi.org/10.1080/10942912.2021.1977655
  9. Kass, L., Weekes, J. & Carpenter, L. (2012) “Effect of magnesium supplementation on blood pressure: a meta-analysis.” European Journal of Clinical Nutrition, 66 , 411–418. doi.org/10.1038/ejcn.2012.4 
  10. Schulz, R., R e Triggle, C. (1994). “Role of NO in vascular smooth muscle and cardiac muscle function.” Trends in Pharmacological Sciences, 15 (7), 255-259. doi.org/10.1016/0165-6147(94)90321-2.
  11. Kucukguven, A. e Khalil, RA. (2013) “Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.” Curr Drug Targets, 14(3), 287-324. PMID: 23316963; PMCID: PMC3584231.
  12. Cacione D., Novaes F., Silva J. (2020). “Correlation between presence of lower limb varicose veins and deep venous thrombosis”. J Vasc Bras, 31(19)e20200081. doi: 10.1590/1677-5449.200081. 
  13. Almeida, M., Guillaumon A., Miquelin D. et al. (2019). “Guidelines for superficial venous thrombosis.” J Vasc Bras, 20(18)e20180105. doi: 10.1590/1677-5449.180105. 
  14. Moser K., Fedullo P., LitteJohn J. e Crawford R. (1994) “Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis.” JAMA, 271(3), 223-5. PMID: 8277550.